Small cell lung cancer · line 1 · Etoposide-platinum + durvalumab (extensive SCLC, 1L)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	standard
Linked regimen	`REG-EP-DURVA-SCLC`

ID	`IND-SCLC-EXTENSIVE-1L`
Type	Indication
Status	status not declared
Diseases	`DIS-SCLC`
Sources	`SRC-ESMO-SCLC-2021` `SRC-NCCN-SCLC-2025`

Notes

CASPIAN durvalumab preferred per ESMO; NCCN considers EP+atezo (IMpower133) and EP+durva (CASPIAN) equivalent. Choice institutional.

Used By

Algorithms

ALGO-SCLC-1L - ALGO-SCLC-1L